PolyTherics Moves Lead Candidate into Development and Manufacturing with DSM BioSolutions
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
DSM BioSolutions, DSM’s microbial fermentation CMO business unit and PolyTherics Limited (PolyTherics), have announced that they have entered into an agreement for the process development and manufacture of PolyTherics’ lead biobetter product, HiPEG™ IFN a-2a.
PolyTherics has applied its HiPEG™ site-specific PEGylation technology to interferon alpha to produce a product (HiPEG™ IFN a-2a) that has eight-fold higher activity than a marketed PEGylated interferon in vitro and a comparable half-life in a preclinical study.
HiPEG™ specifically attaches poly(ethylene) glycol (PEG) to a histidine tag at the end of the protein; histidine tags are commonly used to improve protein stability and to facilitate the purification of proteins. PolyTherics is seeking partners for the development of HiPEG™ IFN a-2a for hepatitis C.
DSM has successfully started development, scale-up and manufacture of the recombinant his-tagged IFN a-2a. PolyTherics will transfer its proprietary HiPEG PEGylation method to DSM so that the process can also be scaled-up. The companies intend to develop a robust process to produce sufficient material for preclinical development and then for cGMP production of HiPEG™ IFN a-2a for clinical development.
Keith Powell, CEO of PolyTherics, stated that: “The transfer of the production of our lead product to a contract manufacturer is a major milestone for PolyTherics and is the beginning of the development stage of its first biobetter drug.”
Villaume Kal, Vice-President of DSM BioSolutions stated: "We are delighted to work with PolyTherics on this promising biobetter compound. Our technology, operational excellence, and outstanding cGMP and compliance record with the EMA and FDA allows us to serve this important customer and to develop, scale-up and manufacture their preclinical and clinical material.”
No financial terms will be disclosed.
PolyTherics has applied its HiPEG™ site-specific PEGylation technology to interferon alpha to produce a product (HiPEG™ IFN a-2a) that has eight-fold higher activity than a marketed PEGylated interferon in vitro and a comparable half-life in a preclinical study.
HiPEG™ specifically attaches poly(ethylene) glycol (PEG) to a histidine tag at the end of the protein; histidine tags are commonly used to improve protein stability and to facilitate the purification of proteins. PolyTherics is seeking partners for the development of HiPEG™ IFN a-2a for hepatitis C.
DSM has successfully started development, scale-up and manufacture of the recombinant his-tagged IFN a-2a. PolyTherics will transfer its proprietary HiPEG PEGylation method to DSM so that the process can also be scaled-up. The companies intend to develop a robust process to produce sufficient material for preclinical development and then for cGMP production of HiPEG™ IFN a-2a for clinical development.
Keith Powell, CEO of PolyTherics, stated that: “The transfer of the production of our lead product to a contract manufacturer is a major milestone for PolyTherics and is the beginning of the development stage of its first biobetter drug.”
Villaume Kal, Vice-President of DSM BioSolutions stated: "We are delighted to work with PolyTherics on this promising biobetter compound. Our technology, operational excellence, and outstanding cGMP and compliance record with the EMA and FDA allows us to serve this important customer and to develop, scale-up and manufacture their preclinical and clinical material.”
No financial terms will be disclosed.
